OrthoPediatrics (NASDAQ:KIDS) Rating Increased to Strong-Buy at TD Cowen

OrthoPediatrics (NASDAQ:KIDS) was upgraded by investment analysts at TD Cowen to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

Several other research analysts have also issued reports on KIDS. Piper Sandler decreased their target price on OrthoPediatrics from $30.00 to $22.00 and set an “overweight” rating for the company in a research report on Friday, October 10th. Lake Street Capital dropped their target price on shares of OrthoPediatrics from $37.00 to $34.00 and set a “buy” rating on the stock in a report on Friday, October 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of OrthoPediatrics in a research note on Thursday, January 22nd. BTIG Research reissued a “buy” rating and set a $23.00 price objective on shares of OrthoPediatrics in a research note on Wednesday, October 29th. Finally, Citigroup restated an “outperform” rating on shares of OrthoPediatrics in a research note on Friday, October 10th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $23.89.

OrthoPediatrics Price Performance

Shares of KIDS stock opened at $17.74 on Tuesday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.52 and a current ratio of 7.40. OrthoPediatrics has a fifty-two week low of $15.28 and a fifty-two week high of $26.40. The firm has a market cap of $444.92 million, a P/E ratio of -9.10 and a beta of 1.09. The business’s 50 day moving average price is $18.06 and its 200-day moving average price is $18.80.

OrthoPediatrics (NASDAQ:KIDS) last posted its earnings results on Tuesday, October 28th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.02. OrthoPediatrics had a negative net margin of 20.06% and a negative return on equity of 6.86%. The firm had revenue of $61.25 million during the quarter, compared to analysts’ expectations of $63.63 million. On average, equities research analysts anticipate that OrthoPediatrics will post -0.93 earnings per share for the current year.

Institutional Trading of OrthoPediatrics

Large investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of OrthoPediatrics by 6.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock worth $246,000 after purchasing an additional 645 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of OrthoPediatrics by 433.1% in the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after acquiring an additional 1,139 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of OrthoPediatrics by 60.2% in the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after acquiring an additional 1,235 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in OrthoPediatrics by 12.4% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,901 shares of the company’s stock valued at $342,000 after purchasing an additional 1,753 shares during the period. Finally, Caption Management LLC purchased a new position in OrthoPediatrics in the 3rd quarter worth approximately $54,000. 69.05% of the stock is currently owned by institutional investors.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.